Semaglutide - Medication and Pregnancy KB

Semaglutide

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Kolding (Controls exposed to insulin), 2025	Denmark 2016 - 2023	All singleton pregnancies surviving the first trimester in the Central Denmark Region, which accounts for one fifth of Denmark's population.	Pregnancies exposed to semaglutide (ATC A10BJ06) during the first trimester (from the estimated conception date to 70 days after, corresponding to gestational age 12 0/7).	exposed to other treatment, sick Pregnancies exposed to insulin with no simultaneous use of semaglutide.	32 / 547	Exposed group: 27 used Ozempic (22 of these in combination with insulin), and five used Wegovy. Seventeen discontinued semaglutide in the first trimester, and 14 used semaglutide throughout all trimesters.
Kolding (Controls unexposed, general pop), 2025	Denmark 2016 - 2023	All singleton pregnancies surviving the first trimester in the Central Denmark Region, which accounts for one fifth of Denmark's population.	Pregnancies exposed to semaglutide (ATC A10BJ06) during the first trimester (from the estimated conception date to 70 days after, corresponding to gestational age 12 0/7).	unexposed (general population or NOS) Pregnancies unexposed to diabetes medications.	32 / 103843	Exposed group: 27 used Ozempic (22 of these in combination with insulin), and five used Wegovy. Seventeen discontinued semaglutide in the first trimester, and 14 used semaglutide throughout all trimesters.
Maya, 2025	USA 2016 - 2025	Singleton pregnancies with delivery dates between June 1, 2016, and March 31, 2025, at Mass General Brigham, an academic health system with 15 institutions serving the greater Boston area in Massachusetts.	Singleton pregnancies with Semaglutide order in the electronic health record (EHR) between 3 years before and 90 days after conception.	unexposed (general population or NOS) Singleton pregnancies without Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications recorded between 3 years before pregnancy and 90 days after conception.	247 / 741

Study

Country
Study period

Population source

Exposure definition

Non-exposure definition

Sample size

Rmk

Denmark
2016 - 2023

All singleton pregnancies surviving the first trimester in the Central Denmark Region, which accounts for one fifth of Denmark's population.

Pregnancies exposed to semaglutide (ATC A10BJ06) during the first trimester (from the estimated conception date to 70 days after, corresponding to gestational age 12 0/7).

exposed to other treatment, sick
Pregnancies exposed to insulin with no simultaneous use of semaglutide.

32 / 547

Exposed group: 27 used Ozempic (22 of these in combination with insulin), and five used Wegovy. Seventeen discontinued semaglutide in the first trimester, and 14 used semaglutide throughout all trimesters.

Denmark
2016 - 2023

All singleton pregnancies surviving the first trimester in the Central Denmark Region, which accounts for one fifth of Denmark's population.

Pregnancies exposed to semaglutide (ATC A10BJ06) during the first trimester (from the estimated conception date to 70 days after, corresponding to gestational age 12 0/7).

unexposed (general population or NOS)
Pregnancies unexposed to diabetes medications.

32 / 103843

USA
2016 - 2025

Singleton pregnancies with delivery dates between June 1, 2016, and March 31, 2025, at Mass General Brigham, an academic health system with 15 institutions serving the greater Boston area in Massachusetts.

Singleton pregnancies with Semaglutide order in the electronic health record (EHR) between 3 years before and 90 days after conception.

unexposed (general population or NOS)
Singleton pregnancies without Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications recorded between 3 years before pregnancy and 90 days after conception.

247 / 741

Case-control studies (cohort)

Study

Country
Study period

Case

Control

Sample size

Rmk

Warning! There are no case-control studies available for this drug.

1 study, not fulfilled eligibility criteria, were excluded. See excluded tab for the list of these studies and reason of exclusion.